Daniel Axelrod
Internal Medicine · Fort Myers, FLNPI 1194723569
Payments from drug & device makers
Across 188 payments — averaging $16.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amarin Pharma, Inc.$511
- GSK$462
- AstraZeneca$318
- Pfizer$289
- Johnson & Johnson$253
- Amgen$164
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,095100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amarin Pharma, Inc. | 24 | $511 |
| GSK | 32 | $462 |
| AstraZeneca | 19 | $318 |
| Pfizer | 22 | $289 |
| Johnson & Johnson | 17 | $253 |
| Amgen | 11 | $164 |
| Novartis | 7 | $144 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $135 |
| Novo Nordisk | 7 | $118 |
| AbbVie(2 entities) | 4 | $90 |
| Lilly USA, LLC | 5 | $76 |
| Merck | 4 | $69 |
| Kowa Pharmaceuticals America, Inc. | 4 | $56 |
| Exact Sciences | 2 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $41 |
| Eisai Inc. | 2 | $36 |
| GE HealthCare | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Bayer | 1 | $25 |
| Corium, LLC | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Abbott | 1 | $18 |
| Nevro Corp. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Resmed Corp | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $11 |
| Antares Pharma, Inc. | 1 | $11 |
How this compares
$3,106 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 35 | $29,957 |
| JardianceEmpagliflozin | 14 | $22,185 |
| XareltoRivaroxaban | 15 | $19,820 |
| JanuviaSitagliptin Phosphate | 12 | $19,057 |
| FarxigaDapagliflozin Propanediol | 12 | $10,591 |
| Gabapentin | 61 | $2,018 |
| Atorvastatin Calcium | 161 | $1,823 |
| Memantine Hcl | 13 | $1,798 |
| SynthroidLevothyroxine Sodium | 21 | $1,626 |
| Rosuvastatin Calcium | 97 | $1,556 |
| Levothyroxine Sodium | 135 | $1,377 |
| Metoprolol Succinate | 78 | $1,256 |
| Amlodipine Besylate | 127 | $983 |
| Tamsulosin Hcl | 61 | $897 |
| Losartan Potassium | 78 | $822 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $289 | $29,95735 claims |
| Johnson & JohnsonXarelto | $253 | $19,82015 claims |
| MerckJanuvia | $69 | $19,05712 claims |
| AstraZenecaFarxiga | $318 | $10,59112 claims |
| AbbVieSynthroid | $90 | $1,62621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Fort Myers
- Yaneicy Gonzalez RojasCoral Gables$93.5M
- Juan Carlos RondonHollywood$66.8M
- Jaynier MoyaPembroke Pines$45.4M
- Mark KutnerMiami$35.7M
- Gilberto JimenezHialeah$35.6M
- Mira BaronWest Palm Beach$29.6M
- William SanchezHialeah$28.9M
- Nelia Sanchez-CrespoHollywood$28.8M
- Kwabena AyesuOrlando$27.6M
- Michael DeverWindermere$24M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.